|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine显示文摘 | Mishra PJ Bertino JR | 2009 | Pharmacogenomics2009，10，3： | 1 |
| 2 | Gatifloxacin-associated corrected QT interval prolongation, torsades de points and ventricular fibrillation in patients with hnown risk factors显示文摘 | JOSEPH S BERTINO JR ROBERT C | 2002 | ID2002，34，15： | 1 |
| 3 | Fluorouracil in colorectal cancer-- a tale of two drugs: implications for biochemical modulation显示文摘 | Sobrero AF Aschele C Bertino JR | 1997 | J Clin Oncol1997，15，1： | 1 |
| 4 | Functional roles of E2F in cell cycle regulation 显示文摘 | Fan J Bertino JR | 1997 | Oncogene1997，14，10： | 1 |
| 5 | Resistance mechanisms to methotrexate in tumors显示文摘 | Goker E Gofliek R | 1996 | Stem Cells1996，14，1： | 1 |
| 6 | Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs显示文摘 | Rogers JF Nafziger AN Jr Bertino JS | 2002 | Am J Med2002，113，15： | 1 |
| 7 | Cancer research:from folate antagonism to molecular targets显示文摘 | Bertino JR | 2009 | Best Pract Res Clin Haematol2009，22，4： | 1 |
| 8 | Function roles of E2F in cell cycle regu- lation显示文摘 | Fan J Bertino JR | 1997 | Oncogene1997，14，10： | 1 |
| 9 | L-asparaginase显示文摘 | Capizzi RL Bertino JR Handschumacher RE | 1970 | Annu Rev Med1970，21，： | 1 |
| 10 | Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation 显示文摘 | Sobrero AF Aschele C Bertino JR | 1997 | J Clin Oncol1997，15，1： | 1 |
| 11 | Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma 显示文摘 | Moskowitz CH Bertino JR Glassman JR | 1999 | J Clin Oncol1999，17，： | 1 |
| 12 | Cancer research: from folale antagonism to molecular targets 显示文摘 | Bertino JR | 2009 | Best Pract Res Clin Haematol2009，22，4： | 1 |
| 13 | Resistance mechanisms to methotrexate in tumors显示文摘 | BERTINO JR GKER E GORLICK R | 1996 | Stem Cells1996，14，1： | 1 |
| 14 | MicroRNA polymorphisms: the future ofpharmacogenornics, molecular epidemiology and individualizedmedicine 显示文摘 | Mishra PJ Bertino JR | 2009 | Pharmacogenornics2009，10，3： | 1 |
| 15 | Limited sampling models for oral midazolam : midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity 显示文摘 | Lee LS Bertino JS Jr Nafziger AN | 2006 | J Clin Pharmacol2006，46，： | 1 |
| 16 | Ifosfamide, carboplatin,and etoposide: a highly eVective cytoreduction and peripheralblood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma 显示文摘 | Moskowitz CH Bertino JR Glassman JR | 1999 | J Clin Oncol1999，17，12： | 1 |
| 17 | Molecular targets for epigenetic therapy of cancer显示文摘 | Humeniuk R Mishra PJ Bertino JR | | 0，，02： | 1 |
| 18 | Hematopoietic stem cell gene therapy with drug resistance genes : an update 显示文摘 | Budak-Alpdogan T Banerjee D Bertino JR | 2005 | Cancer Gene Ther2005，12，11： | 1 |
| 19 | Schedule-de-pendent antitumor effects of methotrexate and5-fluoroura-cil显示文摘 | Bertino JR Sawicki WL Lindquist CA | 1977 | Cancer Res1977，37，1： | 1 |
| 20 | Gatifloxacin- associated corrected Q - T interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors显示文摘 | Bertino J S Jr Owens R C Jr Carnes T D | 2002 | Clin Infect Dis2002，34，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员